Aug. 31 at 4:34 PM
BioAge Labs (
$BIOA ) meets investors at the 5th Annual ROTH Healthcare Opportunities Conference, hosted by ROTH Capital Partners at The Metropolitan Club in New York City on Tuesday, September 29, 2026, where B2i Digital is the Marketing Partner.
The 5th Annual ROTH Healthcare Opportunities Conference is a B2i Digital Featured Conference. See event details and profiles of participating companies at: https://b2idigital.com/5th-annual-roth-healthcare-opportunities-conference
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including retinal diseases such as diabetic macular edema. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers in participants with obesity and elevated inflammatory markers such as hsCRP. Phase 2 proof-of-concept data are anticipated in the second half of 2026, and Phase 1b/2a diabetic macular edema proof-of-concept data are anticipated in mid-2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Credit to the team at ROTH: Byron Roth, Aaron Gurewitz, Isabel Mattson-Pain, Nazan Akdeniz, Otilia "Charo" Montano, Amanda McAdams, James Antonopoulos, Benjamin Bowen, Kris S., Jason Wittes and Boobalan Pachaiyappan, Ph.D.
ROTH built the day around time with management, in a 25-minute 1-on-1 and small group format running from 8:00 AM to 4:30 PM that gives institutional investors extended interaction with the executives running these companies, alongside themed panel discussions and a keynote. This is an invitation-only event and registration is subject to approval by ROTH.
To request registration: https://www.meetmax.com/sched/event_139361/conference_home.html
ROTH is a relationship-driven investment bank focused on serving growth companies and their investors across capital raising, equity research, sales and trading, mergers and acquisitions (M&A) advisory, and corporate access. For more information, visit www.roth.com.
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
